BACKGROUND. Whether patients in clinical remission for acute lymphoblastic leukemia (ALL) continue to harbor leukemic cells is not known, because methods of detecting residual malignant cells have not been sufficiently sensitive. This information might be useful for predicting recurrence and determining the duration of therapy. METHODS. Using a sensitive new method--identifying complementarity-determining region III sequences with the polymerase chain reaction--we estimated the number of residual leukemic cells in the bone marrow of eight children with B-lineage lymphoblastic leukemia before and after remission. RESULTS. Induction chemotherapy produced a 3-to-4-log reduction in the number of leukemic cells. In all samples obtained up to 18 months after diagnosis, however, 0.004 to 2.6 percent of bone marrow nucleated cells were residual leukemic cells. Among the four patients studied more than 18 months after diagnosis, three had no detectable leukemic cells in marrow samples. Despite this, one of them, who was no longer receiving therapy, had a central nervous system relapse. In one patient receiving maintenance chemotherapy, there was a 60-fold increase in leukemic cells three months before bone marrow relapse. CONCLUSIONS. The complete disappearance of leukemic cells (or their reduction below our method's threshold of detection, 1 in 100,000 cells) may be necessary to achieve a cure of ALL. The quantification of residual leukemic cells in serial marrow aspirates during therapy may allow the early detection of relapse.
Source Information
Wistar Institute, Philadelphia, PA 19104.
This article has been cited by other articles:
Zhou, J., Goldwasser, M. A, Li, A., Dahlberg, S. E., Neuberg, D., Wang, H., Dalton, V., McBride, K. D, Sallan, S. E., Silverman, L. B, Gribben, J. G., for the Dana-Farber Cancer Institute ALL Consortiu,
(2007). Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood
110: 1607-1611
[Abstract][Full Text]
Nyvold, C., Madsen, H. O., Ryder, L. P., Seyfarth, J., Svejgaard, A., Clausen, N., Wesenberg, F., Jonsson, O. G., Forestier, E., Schmiegelow, K.
(2002). Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood
99: 1253-1258
[Abstract][Full Text]
Cave, H. C., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B., Vilmer, E., Nelken, B., Fournier, M., Boutard, P., Lebrun, E., Mechinaud, F., Garand, R., Robert, A., Dastugue, N., Plouvier, E., Racadot, E., Ferster, A., Gyselinck, J., Fenneteau, O., Duval, M., Solbu, G., Manel, A.-M., The European Organization for Research and Treatme,
(1998). Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. NEJM
339: 591-598
[Abstract][Full Text]
Hunger, S. P., Fall, M. Z., Camitta, B. M., Carroll, A. J., Link, M. P., Lauer, S. J., Mahoney, D. H., Jeanette Pullen, D., Shuster, J. J., Philip Steuber, C., Cleary, M. L.
(1998). E2A-PBX1 Chimeric Transcript Status at End of Consolidation Is Not Predictive of Treatment Outcome in Childhood Acute Lymphoblastic Leukemias With a t(1;19)(q23;p13): A Pediatric Oncology Group Study. Blood
91: 1021-1028
[Abstract][Full Text]
Frickhofen, N., Muller, E., Sandherr, M., Binder, T., Bangerter, M., Wiest, C., Enz, M., Heimpel, H.
(1997). Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia. Blood
90: 4953-4960
[Abstract][Full Text]
Dibenedetto, S. P., Lo Nigro, L., Pine Mayer, S., Rovera, G., Schiliro, G.
(1997). Detectable Molecular Residual Disease at the Beginning of Maintenance Therapy Indicates Poor Outcome in Children With T-Cell Acute Lymphoblastic Leukemia. Blood
90: 1226-1232
[Abstract][Full Text]
Vitetta, E. S., Tucker, T. F., Racila, E., Huang, Y.-W., Marches, R., Lane, N., Scheuermann, R. H., Street, N. E., Watanabe, T., Uhr, J. W.
(1997). Tumor Dormancy and Cell Signaling. V. Regrowth of the BCL1 Tumor After Dormancy Is Established. Blood
89: 4425-4436
[Abstract][Full Text]
Roberts, W. M., Estrov, Z., Ouspenskaia, M. V., Johnston, D. A., McClain, K. L., Zipf, T. F.
(1997). Measurement of Residual Leukemia during Remission in Childhood Acute Lymphoblastic Leukemia. NEJM
336: 317-323
[Abstract][Full Text]
Greaves, M.
(1997). Silence of the Leukemic Clone. NEJM
336: 367-369
[Full Text]
Previous
